Molecular docking, synthesis and preliminary pharmacological evaluation of new (2-methyl benzimidazole-1-yl )-N- derivatives having imidazolidinone moiety
Pages 1132-1145
https://doi.org/10.22034/crl.2025.494517.1496
Mariam Saeb Jasim, Monther Faisal Mahdi, Fouad A. AL-Saady
Abstract Abstract :
Cancer represents a critical global health challenge, requiring the development of effective targeted therapeutics. Receptor tyrosine kinases (RTKs) play critical roles in cancer cells proliferation and survival; among them, one of the most studied RTK related to cancer cell biology is the epidermal growth factor receptor (EGFR).Receptor tyrosine kinases (RTKs) are integral to the proliferation and survival of cancer cells, with the epidermal growth factor receptor (EGFR) being one of the most extensively studied RTKs in this regard. This study, therefore, aims to design, synthesize, and evaluate novel benzimidazole-based compounds as potential EGFR inhibitors. We devised and synthesized a series of benzimidazole derivatives that incorporate the imidazolidinone pharmacophore. Molecular docking studies were conducted using the GOLD program to predict the binding interactions within the active site of EGFR. Results from the docking analysis indicated that these derivatives exhibited favorable binding affinities and interactions with critical residues, suggesting their potential as EGFR inhibitors. All synthesized compounds were characterized using a range of spectroscopic techniques, including FT-IR and ¹H-NMR, confirming the structural integrity of the compounds. Furthermore, in vitro studies have been initiated to assess the anti-proliferative activities against various cancer cell lines.
This research offers valuable insights into the design and development of novel EGFR inhibitors. The compounds identified exhibit potential as therapeutic agents for cancer treatment and warrant further investigation and optimization.


















